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Abstract
Background: The expression of BCL11B was reported in T-cells, neurons and keratinocytes. Aberrations of BCL11B locus
leading to abnormal gene transcription were identified in human hematological disorders and corresponding animal
models. Recently, the elevated levels of Bcl11b protein have been described in a subset of squameous cell carcinoma cases.
Despite the rapidly accumulating knowledge concerning Bcl11b biology, the contribution of this protein to normal or
transformed cell homeostasis remains open.
Methodology/Principal Findings: Here, by employing an overexpression strategy we revealed formerly unidentified
features of Bcl11b. Two different T-cell lines were forced to express BCL11B at levels similar to those observed in primary T-
cell leukemias. This resulted in markedly increased resistance to radiomimetic drugs while no influence on death-receptor
apoptotic pathway was observed. Apoptosis resistance triggered by BCL11B overexpression was accompanied by a cell
cycle delay caused by accumulation of cells at G1. This cell cycle restriction was associated with upregulation of CDKN1C
(p57) and CDKN2C (p18) cyclin dependent kinase inhibitors. Moreover, p27 and p130 proteins accumulated and the SKP2
gene encoding a protein of the ubiquitin-binding complex responsible for their degradation was repressed. Furthermore,
the expression of the MYCN oncogene was silenced which resulted in significant depletion of the protein in cells expressing
high BCL11B levels. Both cell cycle restriction and resistance to DNA-damage-induced apoptosis coincided and required the
histone deacetylase binding N-terminal domain of Bcl11b. The sensitivity to genotoxic stress could be restored by the
histone deacetylase inhibitor trichostatine A.
Conclusions: The data presented here suggest a potential role of BCL11B in tumor survival and encourage developing
Bcl11b-inhibitory approaches as a potential tool to specifically target chemoresistant tumor cells.
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Introduction
The BCL11B gene encodes a protein which was originally
described as chicken ovalbumin upstream promoter transcription
factor (COUP-TF)-interacting protein 2 (CTIP2) [1] and radiation
induced tumor suppressor gene 1 (RIT1) [2]. Bcl11b belongs to
C2H2-zinc finger Krueppel-like proteins, the largest family of
transcription factors in eukaryotes. DNA binding is mediated via
amino acids on the surface of an alpha-helix [3,4]. Apart from the
DNA binding region, Bcl11b possesses domains responsible for
transcriptional regulation. The catalogue of proteins and protein
complexes known to interact with Bcl11b has grown recently. It
includes COUP-TF [5], the nucleosome re-modeling and histone
deacetylation complex (NuRD) [6] and the ubiquitous transcription
factor Sp1 [7]. Furthermore, recruitment of histone deacetylases
(HDAC1 and HDAC2, resp. SIRT1) [6,8] and the histone
methyltransferase SUV39H1 by Bcl11b induces heterochromatin
formation and makes it a potent transcriptional repressor [9].
Conversely, Bcl11b interaction with p300 co-activator on the
upstream site 1 (US1) of the IL-2 promoter results in transcriptional
activation of IL-2 expression in activated T-cells [10]. Interestingly,
although interaction partners and their binding sequence have been
revealed only a few direct target genes of BCL11B have been
discovered to date. The P57/KIP2 gene, i.e., a cyclin-dependent
kinase inhibitor, is suppressed by Bcl11b [11]. In addition to P57
and IL-2 genes, the cancer Osaka thyroid oncogene (Cot) has been
recently identified as a direct transcriptional target of Bcl11b.
Similar to IL-2, the engagement of Bcl11b on the Cot promoter
region ledto inductionof Cotexpression and itskinaseactivity.This
caused an augmented phosphorylation of IkappaB kinase which
resulted in increased translocation of NF-kappaB to the nucleus and
activation of its target genes [12]. The number of Bcl11b-regulated
geneswasrecentlyextendedtoinclude themajorcell cycle regulator
andtumorsuppressorCDKN1A/p21WAF1whichwasdemonstrated
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and methyltransferases to the p21WAF1 promoter [13].
The list of biological processes requiring BCL11B is constantly
expanding. It includes the regulation of T-cell differentiation [14],
normal development of central nervous system (CNS) during
embryogenesis [15,16] and the maintenance of the latent state of
human immunodeficiency virus (HIV) infections [9]. Of note,
BCL11B which has initially been thought to be of importance to
the immune and central nervous systems seems to have a con-
siderably broader impact. The results published within the last
years showed the requirement for BCL11B in developing skin [17],
where it regulates keratinocyte proliferation and the late dif-
ferentiation phases determining the process of skin morphogenesis
[18]. Moreover, normal tooth development also required BCL11B
expression and was significantly impaired in BCL11B-deficient
mice which was accompanied by the decreased expression of
ameloblast marker genes and transcription factors driving
odontogenesis [19]. The rapidly growing relevance of BCL11B
for the normal development of different organs and pathogenesis
of various diseases requires further investigation of cellular and
molecular mechanisms involving Bcl11b.
The recently acquired and already established data suggest a
critical role of BCL11B in three major cellular processes: pro-
liferation, survival and differentiation. The BCL11B knockout
mouse model revealed the apoptotic phenotype of Bcl11b
2/2
thymocytes accompanied by decreased expression of BCLxL and
BCL-2 genes [14]. The earlier finding that ectopic expression of
BCL11B in HeLa cells caused cell cycle retardation inspired the
authors to develop a hypothesis of unscheduled proliferation as a
primary cause of cell death in Bcl11b-depleted cells. The suppres-
sive influence of accumulated Bcl11b on cell cycle progression was
later confirmed in a hematopoietic cell line [20]. However, the
mechanism responsible for the reduced proliferation has not been
elucidated to date. Moreover, the recently described Bcl11b-
mediated transcriptional repression of P57/KIP2 and p21WAF1
cyclin-dependent kinase inhibitors responsible for cell cycle restric-
tion should lead to effects opposite to the observed cell cycle
retardation [13,21].
Using a RNA interference approach, we could reproduce the
apoptotic phenotype in transformed T cell lines but not in normal
mature cells which suggested that apoptosis following Bcl11b
depletion is transformation-dependent [22]. These data were
confirmed by other reports showing not only reduced survival
associated with BCL11B knockdown but also impaired response to
DNA damage, disabled checkpoint activation and replication
stress [23]. These two reports emphasize the anti-apoptotic role of
Bcl11b but also uncover its potential function in maintaining
genome stability, two features which might contribute to the
malignant transformation.
The role of BCL11B in the pathogenesis of hematological
diseases is still a matter of debate. In humans overexpression of
BCL11B has been linked to lymphoproliferative disorders like the
T-cell acute lymphoblastic leukemia (T-ALL) [24,25] and an acute
form of adult T-cell leukemia/lymphoma [26]. Furthermore,
BCL11B induction correlated with the low differentiation status in
head and neck squamous cell carcinoma where Bcl11b co-localized
with the cancer stem cell marker BMI-1 [27]. In contrast, mouse
models of T-cell leukemia revealed frequent homozygous deletions
or mutations within the BCL11B locus [28]. Moreover, the loss of
one allele was identified as a factor predisposing to lymphoma
development in p53 (+/2) mice which implicated that BCL11B is a
haploinsufficient tumor suppressor for thymoma progression in this
genetic background and that deletion of one gene copy supports
uncontrolled growth [29]. These inconsistencies between animal
models and human diseases intensify the dispute on oncogenic or
anti-neoplastic properties of BCL11B.
Here we show that BCL11B possesses features which, depending
on the expression level and the cellular context, could predispose it
to the role of both tumor suppressor and a gene supporting
survival of transformed cells. Employing the gene overexpression
strategy we demonstrated the relevance of Bcl11b in cell cycle
control, chemoresistance and cell death. Our data provide further
encouragement for the development of BCL11b-targeting, anti-
neoplastic strategies. The attractiveness of such approaches
increases together with the accumulating proofs for BCL11B’s
role in different malignant diseases.
Results
Elevated level of Bcl11b protects transformed T cells from
DNA-damage-induced apoptosis but does not interfere
with death-receptor pathway
The mechanisms of cell death caused by Bcl11b-depletion were
already described, but the potential contribution of elevated Bcl11b
to cell survival and proliferation has not been explored in detail yet.
To address this question, we developed the retroviral-vector-based
BCL11B overexpression system in two different T cell lines: Jurkat
and huT78. The transduction efficiency monitored by measure-
ments of green fluorescence encoded by the reporter gene GFP
reached 85% (Fig. 1a). This resulted in an over 20-fold upregulation
of BCL11B mRNA expression which reached (huT78) or exceeded
(Jurkat) the average expression level measured in primary T-cell
leukemia samples (Fig. 1b). On protein level a 3–5 fold increase of
the Bcl11b-specific signal wasobserved (Fig. 1c). To ensure an equal
and high transgene expression and the reproducibility of further
experiments, mock and BCL11B-transduced cells were additionally
sorted by FACS to eliminate non-modified cells.
The elevated Bcl11b level itself did not cause significant
difference in cell viability compared to mock-transduced cells as
measured by Annexin-V binding assay. In contrast, induction of
apoptosis with DNA-damaging agents such as etoposide (ETO)
and camptothecin (CAM) was ineffective in Jurkat and huT78 cells
expressing high levels of BCL11B compared to the parental cell
lines (Fig. 2a). This finding was confirmed for a broad range
of ETO and CAM concentrations (Fig. 2b) and for other
radiomimetic agents like actinomycin D or dihydroethidium (not
shown).
We next investigated whether forced expression of BCL11B
changed only the kinetics of cell death or whether it could also
influence the long-term survival upon genotoxic stress. The mock-
and BCL11B-transduced cells were treated with etoposide for 6h
after which the drug was removed by washing. The survival rate was
assessed by counting live cells every 48h for 2 weeks. The 6h
treatmentdisabled expansion ofmocktransducedcells whilethe cells
with elevated Bcl11b restarted proliferation after 4–7 days (Fig. 2c).
The same approach employing camptothecin and actinomycin D
validated these findings (not shown). This observation supports the
notion that Bcl11b not only altered the kinetics of apoptosis induced
by DNA damage but also allowed the survival of cells temporarily
exposed to genotoxic stress.
To acquire more insight into the Bcl11b-mediated apoptosis
resistance, we exposed the cells to the death-receptor ligand
TRAIL. Surprisingly, we did not observe any protection against
TRAIL treatment in BCL11B-transduced cells neither at low nor
at high doses (Fig. 2d). This indicated that Bcl11b provided
selective resistance to genotoxic stress while it had no effect on
apoptosis triggered by death-receptors.
Bcl11b Causes Chemoresistance
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induced cell death
To explore possible mechanisms of enhanced survival in
BCL11B overexpressing cells exposed to genotoxic stress we
Figure 1. Evaluation of retrovirus-mediated BCL11B transfer
into Jurkat and huT-78 cell lines. (A) The cells transduced with
empty (mock) or BCL11B-encoding retroviral vector were analyzed by
FACS 48h after transduction. The gene transfer efficiency was evaluated
by measuring the percentage of GFP-positive cells. Non-treated (NT)
parental cell lines served as background fluorescence control (B) The
level of BCL11B mRNA was determined by semi-quantitative RT-PCR
assay using b-2-microglobulin as a reference gene in mock-transduced
(JM, HM) or BCL11B-transduced cell lines (JMB, HMB). For comparison
BCL11B expression was measured in 20 primary T-cell leukemia cases (T-
ALLs) (C) The overexpression of BCL11B was confirmed on protein level
by immunodetection using the polyclonal anti-Bcl11b rabbit antibodies.
The equal protein loading was confirmed by detecting b-actin.
doi:10.1371/journal.pone.0012532.g001
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ETO or CAM treatment the activity of caspase 3 assessed by
immunodetection with antibodies raised against the active/cleaved
variant was markedly lower in cells transduced with the BCL11B-
encoding vector (Fig. 3a). Also the apical caspase 9 acting on the
intrinsic DNA-damage-induced apoptotic pathway showed re-
duced activity in the same conditions (Fig. 3b). Labeling of the cells
with the live-mitochondria-specific dye Mitotracker DeepRed
revealed a significant loss of mitochondrial integrity in mock-
transduced cells while in BCL11B-overexpressing cells the pattern
of staining remained unchanged after CAM treatment (Fig. 3c).
Moreover, the activation of Bak-1, a pro-apoptotic member of the
Bcl-2 protein family, which initiates the loss of mitochondrial outer
membrane potential (MOMP) as a result of DNA damage, was
evident in cell expressing endogenous levels of BCL11B but only
minor in cells with elevated Bcl11b (Fig. 3d). Sensitization of cells
to DNA-damage induced apoptosis with the Bcl-2/BCLxL
inhibitor ABT-737 did not overcome the protective effect of
Bcl11b at low to intermediate concentrations. However, high
doses of the drug induced cell death efficiently in both mock- and
BCL11B-transduced cells (Fig. 3e). In contrast to DNA damage,
apoptosis initiated by TRAIL treatment proceeded unperturbed
regardless of BCL11B expression. Both the effector caspase 3 and
the apical caspase 8 were efficiently activated in mock- and
BCL11B-modified cells, in line with previously observed equal
Annexin-V binding (Fig. 3f).
We next examined the influence of BCL11B expression on
induction of DNA breaks resulting from etoposide and campto-
thecin treatment. The immunostaining for phosphorylation of
histone H2AX (cH2AX), an early indicator of the cellular
response to DNA damage, showed marked accumulation of
cH2AX in cells with endogenous levels of Bcl11b while the cells
with elevated Bcl11b showed only weak increase of cH2AX
(Fig. 3g). In order to exclude the detection of apoptosis-related
secondary DNA lesions, the measurements were performed before
the first signs of apoptosis were detectable (Fig. 3g insets).
Alternatively, to prevent the DNA breaks resulting from ongoing
apoptosis, the same experiment was performed in the presence of
pan-caspase inhibitor Z-VAD. Also under these conditions,
BCL11B-overexpressing cells acquired less damage upon genotoxic
stress (data not shown).
Together, these results suggested a role of BCL11B in preventing
DNA-damaged-induced apoptosis at its early initiation stage.
Conversely, the death-receptor triggered apoptosis remained
unaffected.
Bcl11b delays cell cycle progression
The analysis of DNA content revealed that in both cellular
models induction of BCL11B caused slight but significant
accumulation of cells at G1 phase of cell cycle. To exclude the
possibility that increased number of G1 cells resulted from
accelerated cell divisions the cells were treated with a mitosis
inhibitor nocodazol. The measurements performed after nocoda-
zol treatment showed that while all mock-transduced cells entered
cell cycle and reached either late S or G2/M phase within
12 hours, approximately 20–30% of cells with elevated Bcl11b
levels remained at G1 (Fig. 4a). This was further demonstrated by
the 3h pulse-labeling of the cells with the nucleotide analog BrdU
followed by its immunodetection and FACS measurement. The
number of BrdU-negative counts was significantly higher in
BCL11B-transduced cells compared to cells with wild-type level of
the gene (Fig. 4b). This suggested that forced expression of
BCL11B caused either G1 arrest or a delayed G1 to S-phase
transition in a fraction of cells.
The whole-genome expression profiles of mock- and BCL11B-
transduced Jurkat cells uncovered the regulation of genes known to
be involved in cell cycle control (GEO accession number:
GSE21382). The list of genes verified by semi-quantitative RT-
PCR (sqRT-PCR) is presented in Table 1. Our attention focused
on genes with previously confirmed function in G1 or G1 to S-
phase transition. First, the induction of two cyclin dependent
kinase inhibitors CDKN1C (p57) and CDKN2C (p18) was confirmed
on protein level by Western Blotting in both experimental models
(Fig. 5a). While verifying the involvement of the other members of
this gene family we found significant accumulation of CDKN1B
(p27) which resulted either from increased stability or defective
degradation since no major increase of p27 mRNA could be
measured (data not shown). The later possibility seemed more
likely since the transcriptional downregulation of the SKP2 gene
involved in proteasomal degradation of p27 was identified.
Moreover, the level of Skp2 declined markedly upon BCL11B
induction (Fig. 5b).
Interestingly, in Jurkat cells we did not find any differences in
pRB phosphorylation status which usually precedes the cell cycle
entry. This was confirmed by using phospho-specific antibodies
labeled with fluorescent dyes followed by FACS analysis in the
other cellular system (Fig. 5c). The level of retinoblastoma-like
protein 1 (RBL1, p107) did not vary either (not shown). However,
the third member of this gene family RBL2 (p130), normally
undergoing degradation during cell cycle entry, showed signifi-
cantly increased protein levels (Fig. 5c). This suggested the
possible involvement of pocket proteins and their target genes –
E2Fs in cell cycle delay resulting from BCL11B induction. This
assumption was further strengthened by the 3-fold reduction in
the level of the MYCN oncogene which is negatively regulated by
Rbl2 [30]. The decreased MYCN transcription was confirmed in
BCL11B-overexpressing cells in both experimental models by
sqRT-PCR and verified on protein level by Western blotting in
Jurkat cells. Moreover, the detection of the Myc-n protein by
immunofluorescence followed by FACS revealed a negative
correlation between the Myc-n signal and the intensity of the
reporter gene formerly shown to correspond to Bcl11b levels
(Fig. 5d). This indicated that elevated Bcl11b, apart from
inducing p18, p27 and p57 could delay the cell cycle entry by
causing accumulation of RBL2 which suppressed MYCN
expression. The upregulation of the HBP1 transcription factor
(Table 1.) known to cooperate with RBL2 in suppressing the
MYCN promoter [30] strongly implied the potential involvement
of the Bcl11b-p130/Hbp1-Myc-n axis in the observed G1 arrest/
delay.
Figure 2. Influence of Bcl11b level on apoptosis and cell
survival. (A) Mock- and BCL11B-transduced cells were treated or not
with etoposide (10 mM) and camptothecin (2 mM). The influence of the
treatment on cell viability was evaluated 6h later using a allophyco-
cyanin-labeled Annexin-V binding assay and subsequent FACS analysis.
The data represent one of at least three independent experiments. (B)
The 6 hours etoposide and camptothecin treatments followed by the
Annexin-V binding assay were performed using increasing concentra-
tions of the radiomimetic drugs. (C) Mock- or BCL11B-transduced Jurkat
and huT-78 cells were pulse-treated with 50 mM etoposide. The survival
rate was determined by live cell counting performed every 48h after
etoposide removal. (D) The cells with endogenous and elevated BCL11B
expression were incubated with increasing amounts of the recombinant
tumor necrosis factor related apoptosis inducing ligand (rTRAIL) for 6h.
The procedure was followed by FACS-based Annexin-V binding
detection. The data shown in B, C and D represent mean values 6
standard deviations (SD) obtained from at least three independent
experiments. Statistical significance was calculated using t-Student test.
*p,0.01.
doi:10.1371/journal.pone.0012532.g002
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cycle restriction which included activation or induction of p18 and
p57 cyclin dependent kinase inhibitors, accumulation of p27 p130
and suppression of MYCN oncogene. The increase of cells at G1
phase and decreased fraction of replicating cells couldexplain the low
toxicity of radiomimetic treatment with etoposide and camptothecin.
Figure 4. The impact of Bcl11b level on cell growth. (A) Jurkat and huT-78 cells with endogenous and enforced BCL11B expression were
blocked at G2/M phase of cell cycle using mitosis inhibitor nocodazole (0,5 mM). The cell cycle distribution was evaluated at 0, 4, 8 and 12h by
propidium iodide (PI) staining of genomic DNA followed by FACS measurement of PI fluorescence. (B) The mock- and BCL11B-transduced cells were
incubated with the nucleotide analogue BrdU for 3h followed by fixation and permeabilization procedure. The incorporation of BrdU into genomic
DNA reflecting the proliferative activity was demonstrated using a BrdU-specific, APC-labeled antibody (y axis). Total genomic DNA was stained with
7-aminoactimomycin D (7-AAD, x axis). These results are representative of at least three independent experiments.
doi:10.1371/journal.pone.0012532.g004
Figure 3. Investigation of DNA-damage- and TRAIL-induced apoptosis pathways. (A) Jurkat and huT-78 cells expressing normal and high
BCL11B levels were incubated with ETO and CAM for 4h. The cleaved (active) form of Caspase 3 was stained using a fluorescently labeled antibody
and measured by FACS in fixed/permeabilized cells. (B) Protein lysates obtained from the cells exposed to ETO and CAM for 4h were checked for the
presence of activated Caspase 9 by immunodetection of its cleaved variant with Western Blotting. (C) A portion of mock- and BCL11B-modified cells,
treated or not with ETO and CAM for 2h was incubated with the intact-mitochondria-accumulating dye (Mitotracker) for 1h. The accumulation of the
dye reflecting the non-disrupted state of mitochondrial membranes was measured by FACS 3h after triggering DNA damage. (D) At the same time-
point, a fraction of fixed and permeabilized cells was stained using the antibody recognizing the activated variant of Bak-1 protein. (E) Jurkat and
huT-78 cells with endogenous and increased BCL11B expression were incubated with growing concentration of Bcl-2 and Bcl-xL inhibitor ABT-737
and treated or not with Eto (10 mM) or CAM (2 mM). 6h later the viability of the cells was tested using Annexin-V binding assay followed by FACS
analysis. (F) The cell transduced with empty- or transgene-encoding vectors were incubated with 50 ng/ml rTRAIL, collected, fixed and permeabilized
4h after initiation of treatment. The activation of Caspase 8 and Caspase 3 was determined using cleaved variant-specific antibodies followed by FACS
measurement. (G) The mock- and BCL11B-modified cells were treated with ETO and CAM and two hours after drug administration the cells were
tested for viability using a Annexin V-binding assay (insets). The remaining cells were fixed/permeabilized and stained with a phospho-specific,
AlexaFluor-647-labeled H2AX (cH2AX) antibody. The cH2AX-positive cells were detected by FACS analysis. Parts A, B, C, D, F and G show data
representative of at least three independent experiments.
doi:10.1371/journal.pone.0012532.g003
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by BCL11B overexpression require its HDAC-interacting
N-terminal domain
Bcl11b was identified as a part of several multiprotein
complexes and a number of Bcl11b domains involved in these
interactions have been identified. Therefore, we were interested in
identifying the region of Bcl11b relevant for binding complexes/
proteins necessary for the DNA-damage resistance and/or cell
cycle restriction following its overexpression. We designed, cloned
and expressed three different BCL11B variants covering the
regions known to be important for the formerly established
Figure 5. Regulation of cell cycle-controlling genes following Bcl11b accumulation. (A) The protein lysates acquired from mock- and
BCL11B-transduced Jurkat and huT-78 cells were analyzed by Western blotting using indicated antibodies 48h post-transduction. (B) The effects of
BCL11B overexpression on ubiquitin ligase SKP2 was evaluated by semi-quantitative RT-PCR and western blot 48h after transduction. (C) The
retinoblastoma protein phosphorylation status was assayed using antibodies preferentially binding to hypophosphorylated variant of pRb followed
by flow cytometry. Additionally, the antibodies recognizing specifically the phosphorylated pRb and total retinoblastoma-like protein 2 were usedt o
detect the proteins by western blot. (D) The amount of Myc-N protein in cells with normal and elevated Bcl11b levels were assessed by
immunodetection in protein lysates (upper part, western blot). In addition, a Myc-N-specific antibody was used for intracellular staining followedb y
flow cytometry (lower panel, density plot shows reporter gene – X axis, and Myc-N – Y axis). All western blot and FACS data shown on this figure
represent results obtained from at least three experiments. Section B (upper part, semi-quantitative RealTime RT-PCR) shows average values from
three experiments 6 SD, *p,0.05.
doi:10.1371/journal.pone.0012532.g005
Bcl11b Causes Chemoresistance
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variant one encoded the NuRD interacting N-terminal domain
(BCL11B DC-1), the longer variant 2 contained additionally the
SUV39H1/HP1/SIRT1/Sp1 /Tat binding domain consisting of
the proline-rich region and two central zinc fingers (BCL11B DC-
2). The third mutant allele contained the whole coding sequence
excluding the N-terminal part (BCL11B DN). The constructs were
used for transduction of Jurkat and huT-78 cells and the protein
expression and the calculated molecular weight was confirmed by
Western blot analysis (Fig. 6b.). To test the sub-cellular localization
the deletion mutants were sub-cloned in frame into the pEGFP-C1
vector and transfected by nucleofection into Jurkat cells. As shown
on Fig. 6c, the transfection of EGFP-only vector (mock) caused
even distribution of green fluorescence protein within the cells. In
contrast, when fused to wild-type BCL11B cDNA the EGFP
was located in the nucleus showing the spackle-like structures
previously described by others. A pattern similar to the wild-type
pattern could be detected in cells transfected with BCL11B DC-2
and BCL11B DN deletion mutants. Contrary, the N-terminal part
(BCL11B DC-1) localized in the extranuclear compartment. These
data indicated that the nuclear localization signal was located
downstream of NuRD-interacting N-terminal domain and its
deletion caused aberrant non-physiological location of the fusion
protein.
Next we investigated whether and to which extent the N- and
C-terminally truncated BCL11B variants preserved the properties
of wild-type gene. The induction of DNA damage by the
radiomimetic drug etoposide in cells transduced with empty
vector, wild-type and truncated BCL11B alleles followed by
apoptosis assays confirmed the protective activity of wild-type
BCL11B in both transduced T-cell lines (Fig. 7a.). As expected, the
aberrantly located BCL11B- DC-1 variant did not have any
influence on DNA-damage induced apoptosis. Conversely, the
second C-terminal mutant BCL11B- DC-2 lacking almost half of
the protein including three zinc fingers was as effective in
preventing cell death as its wild-type counterpart. The removal
of the N-terminal domain (BCL11B- DN) in turn resulted in the
complete loss of anti-apoptotic properties. Since we previously
showed that the DNA-damage resistance was accompanied by and
presumably associated with cell cycle restriction at the pre-
replication phase, we performed the synchronization of the
transduced cells at G2/M using nocodazol (Fig. 7b.). DNA
staining before nocodazol treatment showed a slightly elevated
G0/G1 fraction in BCL11B- DC-2 and wild-type BCL11B
transduced cells. Eight hours later the accumulation at late S
and/or G2/M phases and essentially no G0/G1 was observed in
cells transduced with empty, BCL11B- DC-1 and BCL11B- DN-
containing vectors. However, BCL11B- DC-2 and wild-type
BCL11B overexpression caused a significant block of cell cycle at
G0/G1 which correlated well with the DNA-damage resistance.
These results indicated that the anti-apoptotic and cell cycle
regulatory activities of BCL11B are strictly dependent on the
presence of the N-terminal region, previously reported to interact
with protein complexes containing histone deacetylases (HDAC1
and 2). To verify the involvement of HDACs in Bcl11b-mediated
cell cycle control and low sensitivity to genotoxic stress we applied
the histone deacetylase inhibitor trichostatin A (TSA). At high
dose, TSA showed equal toxicity to mock-, BCL11B-WT and
BCL11B-mutant-transduced cells as measured by Annexin V-
binding assay (Fig. 7c.). The sub-optimal dose of TSA caused
generally lower but comparable toxicity (Fig. 7c insets). Besides
this, the low doses of TSA re-sensitized the cells transduced with
BCL11B and BCL11B-DC-2 mutant to etoposide treatment
(Fig. 7c). Similar results were obtained with a different HDAC
class I and II inhibitor SAHA, while a class III inhibitor, blocking
SIRT1 activity was ineffective in interfering with Bcl11b mediated
protection (data not shown). This provided further evidence for the
engagement of HDAC1 and 2 in genotoxic stress resistance and
cell cycle restriction observed upon induction of BCL11B. Of note,
the N-terminal, HDAC-binding region itself was not sufficient for
the described effect. Even when physiologically localized in the
nucleus via addition of the SV40 nuclear localization signal at its
C-terminus it did not alter the DNA-damage sensitivity or cell
cycle progression (not shown).
Discussion
The crucial role of BCL11B gene in the regulation of cell cycle
and apoptosis has been postulated based on the results obtained
from both in vitro and in vivo studies. However, its potential positive
or negative contribution to tumor development was not convinc-
ingly settled so far. The growth-promoting properties of truncated
BCL11B variants isolated from leukemic cells [20], the losses of
heterozygosity at the very early stages of lymphomagenesis [31]
and detection of BCL11B haploinsufficiency for suppression of
mouse thymic lymphomas [29,32] support the speculation of
BCL11B tumor suppressive activity. On the other hand, in the
majority of human T-ALLs the expression of BCL11B was similar
to the level obtained by our overexpression approach in Jurkat and
huT-78 (Fig. 1B). Moreover, amplifications of the BCL11B locus
accompanied by increased mRNA expression and protein were
shown in adult T cell leukemia/lymphoma and correlated with the
Table 1. Cell cycle-related genes identified as at least 2-fold regulated after BCL11B overexpression in Jurkat cells using Affymetrix
Arrays and confirmed by quantitative RT-PCR in independent experiment in two different cellular systems.
Symbol Name
Fold change
(Affymetrix Array)
Fold Change
(qRT-PCR) in Jurkat
Fold Change
(qRT-PCR) in huT-78
MYCN v-myc myelocytomatosis viral related oncogene,
neuroblastoma derived (avian)
22.0 22.4 23.3
BCL6 B-cell CLL/ Lymphoma 6 3.0 3.7 2.5
CCNG2 Cyclin G2 2.9 2.4 4.7
CDKN1C Cyclin-dependent kinase inhibitor 1C 2.1 3.5 2.7
CDKN2C Cyclin-dependent kinase inhibitor 2C 2.1 3.8 3.0
HBP1 HMG-box transcription factor 1 2.6 2.7 2.2
TP53INP1 Tumor protein p53 inducible nuclear protein 1 8.0 6.4 5.2
doi:10.1371/journal.pone.0012532.t001
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opposite to tumor suppression. Diverse Bcl11b features can be
observed also on the biochemical level. Sharing structural
similarities with transcriptional repressors [34] and interacting
with chromatin-silencing protein complexes [35,36,37], Bcl11b
can act also as a potent transcriptional activator [10,12]. The list of
the genes negatively regulated by Bcl11b contains the known
tumor suppressors p57/KIP2 [38] and p21/WAF1 [13], while the
activated targets include genes inducing and regulated by NFkB,
like Cot kinase or IL-2, respectively [10,12]. These data, supported
by the observed elevated expression of BCL11B in T cell
malignancies, imply its pro-survival and growth-promoting
function. The notion was strengthened by findings showing the
critical dependence of transformed T cells’ survival on BCL11B
expression [22,23].
In summary, BCL11B seems to function pleiotropic and may
lead to opposite effects in different cellular systems. This
encouraged us to evaluate the consequences of the increased
BCL11B levels in transformed cells endogenously expressing the
gene. We developed a retrovirus-mediated BCL11B overexpression
system in two different T cell leukemia cell lines and focused our
research on apoptosis and proliferation. We found significantly
increased resistance of BCL11B-overexpressing cells to genotoxic-
stress and cell death which appeared to be blocked at the early
stages of the process. Conversely, apoptosis triggered by death
receptors remained undisturbed suggesting that the enhanced
survival upon genotoxic stress is not due to a general apoptosis
failure. Interestingly, global RNA profiling of wildtype and
BCL11B-overexpressing cells did not reveal any significant dif-
ferences in the expression of genes known to be engaged in the
canonical cell death pathways. The immunodetection of the pro-
and anti- apoptotic members of the BH3-only protein family in
non- or etoposide treated mock- and BCL11B- transduced cells
also did not show any major increase of the anti-/pro-apoptotic
protein ratio (data not shown). The observed lower number
of DNA lesions in BCL11B-overexpressing cells upon damage
induction suggests limited efficiency of the DNA-damaging drugs
as the likely reason for the lower death rate in BCL11B-
overexpressing cells. In light of the previously described growth-
limiting effect of BCL11B in BCL11B-negative HeLa and
hematopoietic progenitor cell FDC-P1lines, a tempting hypothesis
is that cell cycle restriction causes the reduced percentage of S-
phase cells. Since the DNA-damaging treatment we applied was
proven to kill predominantly cells in S-phase [39] the diminished
fraction of cells replicating DNA resulting from G1 accumulation
would lead to the chemoresistance of the non-replicating cell
population. We confirmed this possibility by pre-treating Jurkat
and huT-78 cells with the DNA polymerase inhibitor aphidicolin
which reduced the rate of G1 to S transition and limited
the fraction of S phase cells. When subsequently treated with
etoposide, camptothecin or other radiomimetic drugs a fraction of
cells blocked at G0/G1 phase cells remained vital while the dead
cells originated from S phase (data not shown). The cell cycle
analysis and bromodeoxyuridine (BrdU) incorporation assays
showed a clear decrease of the S phase fraction in both cell lines
upon BCL11B overexpression compared to mock treatment. This
was due to G1 arrest which was most evident when the cells were
synchronized at G2/M with nocodazol which explains the lower
sensitivity to radiomimetic drugs. Of note, the G1 arrest was not
permanent. When pulse-treated with etoposide or other DNA-
damaging drugs, the BCL11B-transduced cells restored growth
after several days while the mock-transduced cells died. This
observation suggests that elevated levels of Bcl11b could trigger a
fraction of chemoresistant tumor-initiating cells. Surprisingly, the
cell cycle arrest seemed not to be accompanied by the activation of
the checkpoint mechanism and the phosphorylation status of the
checkpoint proteins Chk1/Chk2 was not significantly altered (not
shown). This indicates that although the lack of Bcl11b resulted in
checkpoint inactivation [23], the cell cycle delay caused by
BCL11B overexpression was mediated by a Chk1/Chk2 check-
point-independent mechanism. The candidate genes potentially
involved in the observed cell growth suppression were identified by
the comparison of mRNA profiles of mock- and BCL11B-
transduced cells. This analysis revealed upregulated expression
of the G1 cycline-dependent kinase inhibitor CDKN2C (p18/
Ink4c), leading to elevated levels of the encoded protein. The p18
protein binds and inhibits selectively two cyclin dependent kinases,
Cdk4 and 6, which are responsible for controlling G1 to S
transition. The ectopic expression CDKN2C suppresses cell growth
in a manner resembling the activation of the tumor suppressor
gene pRB [40].
Another representative of the CDKis found to be upregulated in
BCL11B-transduced cells is CDKN1C (p57/Kip2). The protein
encoded by this gene is a potent, tight-binding inhibitor of several
G1 CDKs, arresting the cells in G1 when overexpressed [41]. The
induction of this gene in cells with elevated Bcl11b is especially
interesting since the gene has been previously shown to be
negatively regulated by Bcl11b via associating the NuRD
nucleosome remodeling complex [38]. A potential mechanism
which could explain the observed transcriptional activation and
accumulation of p57 could be based on the ‘‘titration’’ model, in
which the accessibility of HDACs necessary for suppression is
limited by an excess of Bcl11b. A depleted activity of HDACs as a
cause of p57 induction was already identified. Different class I and
II HDAC inhibitors showed a potent inducing activity on
CDKN1C. As shown recently, a different member of the
Krueppel-like factor family KLF4 demonstrated a potent anti-
apoptotic effect upon HDACi treatment which was mediated in
part by direct binding and transcriptional upregulation of p57
followed by inhibition of the stress response phosphorylation
pathway [42]. Finally, the role of E2F1 in the transcriptional
regulation of p57 must be considered. We report here the
activation of the Cdk 4/6 inhibitor p18. As communicated
recently, the inhibition of the cyclin dependent kinases by small
Figure 6. Bcl11b deletion mutants: design, expression and localization. (A) Schematic diagram of Bcl11b structure and the BCL11B-derived
deletion mutants; the characteristics of the conserved domains (black boxes) are indicated. Abbreviations: ZnF(s) – zinc finger(s), P-rich – proline- and
S-rich – serine-rich regions. The cooperating proteins are listed above the interacting domains included in the truncated BCL11B variants; HDAC1 and
2 – histone deacetylases 1 and 2, MTA1 and 2 – metastasis-associated gene 1 and 2, Sp1 – transcription factor Sp1, SUV39H1 – suppressor of
variegation 3–9 (homolog of), HIV Tat – human immunodeficiency virus Tat protein, HP1a – heterochromatin protein 1, Sirt1 – sirtuin 1, RbAp46 –
retinoblastoma-binding protein 7, RbAP48 – retinoblastoma-binding protein 4. (B) Jurkat and huT-78 cells were transduced with retroviral vectors
encoding wild-type BCL11B and the BCL11B deletion mutants. The expression of the transgenic proteins was verified by western blot and subsequent
immunodetection using the cocktail of Bcl11b-specific antibodies targeting N-, C-terminal and internal epitopes of the protein. The b-actin protein
level was analyzed to confirm equal protein loading. (C) DNA fragments encoding whole-length and truncated variants of BCL11B were cloned in-
frame into the expression vector downstream of EGFP gene. The vectors were transfected into Jurkat cells and the sub-cellular localization of the
fusion proteins was analyzed by fluorescent microscopy (upper panel). The nuclei were counterstained with the DNA-specific dye DAPI (lower panel).
doi:10.1371/journal.pone.0012532.g006
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involved direct binding of E2F1 to the promoter. It was suggested
that this regulatory loop served to limit the E2F1’s death-inducing
activity [43].
The third member of the cyclin-dependent kinase inhibitors
which accumulated in BCL11B-overexpressing cells was CDKN1B
(p27/Kip1). It was previously reported that downregulation of
Bcl11b led to the transcriptional suppression and decrease of p27
protein [23,44] suspected of being one of the cell-death triggering
events after BCL11B knockdown. This, together with our finding
implied a correlation between Bcl11b and p27 levels. However, we
did not observe an effect of elevated Bcl11b on p27 transcription
indicating the involvement of a post-transcriptional regulation.
The level of p27 protein can be modulated via multiple
posttranscriptional mechanisms [45]. The most potent and the
best characterized mechanism of p27 regulation is its degradation
preceded by polyubiquitylation by the SCF
SKP2-E3 ubiquitin
ligase complex at G1 phase [46]. The involvement of the impaired
Skp2-E3-mediated p27 proteolysis in our system is strengthened
by the fact that SKP2 was significantly reduced on mRNA and
protein level in cells transduced with BCL11B. Support for
functional relevance of the decreased Skp2 level following
BCL11B-transduction was provided by accumulation of another
substrate of the Skp2-E3 complex, the retinoblastoma-like protein
2( RBL2/p130) which was not accompanied by any transcriptional
activation [47]. The increase of p130 protein was the only change
that could be identified within the pocket protein family known
to be crucial for G1 to S transition. However, the accumulation
of p130 could contribute to cell cycle retardation and apoptosis
resistance in BCL11B-transduced cells. In neurons, the integrity of
the E2F4-p130-HDAC/SUV39H1 complex was shown to be
critical for cell survival and overexpression of p130 significantly
increased the apoptosis resistance triggered by camptothecin
treatment [48]. Furthermore, p130 participated in the suppression
of the MYCN promoter by interacting with the HBP1 high
mobility group (HMG) transcription factor increased transcription
of which was observed in BCL11B-overexpressing cells, [30]. The
involvement of the described mechanism in our experimental
system was supported by markedly decreased MYCN transcription
upon BCL11B-transduction. In the cells expressing BCL11B at
higher levels as visualized by the strong EGFP signal, Myc-N
protein was almost undetectable, while the cells with dim green
fluorescence showed stronger signals. This observation argues for a
strict negative correlation between Bcl11b and Myc-N. Interest-
ingly, inactivation of MYCN in vivo led to the activation of p27/
Kip1 and p18/Ink4c [49] which indicates that suppression of
MYCN expression could lead to the effects triggered by BCL11B
overexpression. However, it seems that changes in the level of
Myc-N are not the sole reason for cell cycle abnormalities and cell
death resistance. Overexpression of MYCN markedly increased
proliferation of Jurkat and huT-78 cells expressing endogenous
levels of BCL11B but only minimally influenced the cell cycle
progression in cells transduced with BCL11B-encoding vector (data
not shown). The notion that parallel activation of multiple
pathways seems to lead to the growth suppression and apoptosis
resistance observed after BCL11B overexpression is also supported
by additional studies on CDKis. Neither the specific knockdown of
the particular CDKi nor the simultaneous suppression of two or
three CDKis could restore normal growth or apoptosis resistance.
In order to get more insight into potential mechanisms of
Bcl11b-mediated cell cycle and cell death regulation, we created a
series of BCL11B deletion mutants lacking the important DNA-
binding and protein-interacting domains. Our data strongly
indicate that the identified biological consequences of BCL11B
upregulation were strictly dependent on the presence of the N-
terminal HDAC-interacting domain. The removal of the C-
terminal half of BCL11B cDNA, encoding the three zinc fingers
but carrying the N-terminal domain retained the function of wild-
type BCL11B. Conversely, the deletion of the N-terminal part
completely inactivated the mutant protein, although it localized
physiologically in the nucleus. Interestingly, the short fragment
encoding just the HDAC-interacting region did not show any
BCL11B-resembling activity, even when localized in the nucleus by
addition of viral NLS. Of course one cannot eliminate the
improper folding of such a truncated protein as the reason of its
inactivation.
Taken together, it appears that Bcl11b acts by recruiting some
factors to the DNA template through its HDAC-binding domain.
In order to provide additional support for this hypothetical
mechanism, we treated wt and BCL11B-overexpressing cells with
the HDAC inhibitor trichostatin A (TSA). Unfortunately, we
could not investigate the effects of TSA on cell cycle arrest upon
BCL11B-transduction because of high toxicity of the drug alone
and in combination with the G2/M synchronizing nocodazol.
However, we observed a significant re-sensitization of TSA-treated
BCL11B-overexpressing cells to DNA-damage induced apoptosis,
supporting the involvement of HDAC in Bcl11b-mediated cell
cycle and apoptosis control.
Our results suggest that BCL11B may perform opposite functions
depending on the cellular context and the expression level. The
upregulation of the gene significantly increases the genotoxic stress
resistance which could constitute an oncogenic feature providing
chemoresistance and allowing the survival of transformed cells. On
the other hand, the insensitivity to DNA damage is accompanied by
a markedly lower proliferative activity, which is considered to be
tumor suppressive. We speculate that in non-transformed tissue
BCL11B could control the proliferation, ensure genome stability
and prevent tumor development and/or apoptosis. This feature
qualifies BCL11B as a tumor suppressor or a gene maintaining the
balance between proliferation and cell death. But in the contextof a
tumor tissue BCL11B could act as potential oncogene being an
attractive target for therapeutic approaches.
Similar ambivalent modes of action were identified recently for
p21/WAF1 in a mouse model of leukemia [50]. In this setting a
Figure 7. Bcl11b truncated mutants: apoptosis resistance, cell cycle retardation and HDAC dependence. (A) Jurkat and huT-78 cells
transduced with the empty vector (mock) and constructs encoding the full-length or truncated BCL11B variants were exposed to etoposide for 6h
after which the viability was analyzed by Annexin-V binding assay. (B) The T cell lines expressing endogenous (mock), enforced (BCL11B-WT) and
truncated BCL11B (D) were synchronized at G2/M phase of cell cycle using mitosis inhibitor nocodazole (0,5 mM). The effect of elevated Bcl11b and
Bcl11b-derived mutant proteins on cell cycle was analyzed before and 8h after initiation of nocodazole treatment. The cell cycle distribution was
analyzed by propidium iodide (PI) staining of genomic DNA followed by FACS measurement of PI fluorescence. (C) Jurkat and huT-78 cells transduced
with empty or BCL11B-encoding vectors (wild-type and truncated) were treated for with high dose of histone deacetylase inhibitor trichostatin A
(TSA, left panels) or left untreated (insets). In addition, a lower dose of TSA (150 nM) was combined with the standard etoposide treatment (right
panels). The treatments with TSA- and etoposide-only were performed for comparison (insets). The effects of the drugs on the viability of cells
expressing endogenous, elevated and truncated Bcl11b was measured with Annexin-V binding assay followed by FACS quantification. The data
displayed here represent results obtained from one of at least three separate experiments.
doi:10.1371/journal.pone.0012532.g007
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restricting cell cycle followed by limited DNA damage and
consequently maintaining self-renewal potential of leukemic stem
cells. Of note, BCL11B was found to be co-expressed with the
cancer stem cell marker BMI-1 in a subset of undifferentiated
squamous cell carcinoma cases and cell lines [27]. This indicates
that elevated BCL11B could play a similar role in tumors
expressing it by controlling proliferation and chemoresistance of
tumor-initiating cells. The survival assay presented here seems to
confirm such a possibility. Jurkat and huT-78 cell forced to
overexpress BCL11B survived and efficiently restored cell growth
upon temporal exposition to genotoxic stress.
In conclusion, we believe that the data presented here
strengthen the role of BCL11B in tumor survival rather than
development. Targeting Bcl11b via inhibitory approaches might
be a promising tool for the treatment of rapidly growing list of
cancer types expressing BCL11B. Moreover, the identification of
HDAC-interacting domain of Bcl11b as a critical mediator of its
activity and the finding that BCL11B-mediated apoptosis
resistance can be reversed by HDACi may have important
implication for therapeutic interventions against BCL11B-positive
tumors.
Materials and Methods
Reagents
All biochemicals were from Sigma Chemicals (Munich,
Germany) unless otherwise specified. Human recombinant
TRAIL was purchased from PeproTech (Peprotech Ltd, London,
United Kingdom). The Bcl-2/BCLxL inhibitor ABT-737 was
provided by Abbott (Abbott Laboratories Il, USA).
T-cell leukemia samples
The 20 mRNAs isolated from T-cell lymphoblastic leukemias
were provided by different clinical units. All samples were
obtained according to the guidelines for informed consent
approved by local Ethical Research Committees.
Plasmids
The constructs used in this study were based on the pMSCV-
derived retroviral vector pMIGR encoding internal ribosome
entry site followed by EGFP gene. The sequence encoding the full
length BCL11B was amplified from cDNA prepared from healthy
individual and cloned between BglII and EcoRI restriction sites.
The deletion mutants of BCL11B were constructed using PCR
techniques with proof reading polymerase Pfu (Promega, WI, USA
) using primers equipped with BglII and EcoRI recognition
sequences and start/stop codons where required. All constructs
were checked by sequencing to exclude the presence of mutations.
The vector carrying the pantropic viral envelope protein pVSV-G
was purchased from Clontech (Clontech Laboratories, CA, USA).
Cell culture, transfection and transduction
The human T cell leukemia and lymphoma cell lines Jurkat
(DMSZ, Braunschweig, Germany) and huT-78 (ATCC, Rock-
land, MD) were maintained in RPMI-1640 medium supplemented
with 10% fetal calf serum (PanBiotech Berlin, Germany),
Glutamax (Invitrogen, CA, USA) and Plasmocin (Lonza Scientific,
Switzerland). The retrovirus producing cell line GP2-293
(Clontech Laboratories, CA, USA) was maintained in Dulbecco’s
modified Eagle’s medium (Invitrogen, CA, USA) supplemented as
above.
For recombinant retrovirus production, non-confluent GP2-293
cells were co-transfected with 10 mg of purified pVSV-G and
empty pMIGR plasmid (mock) or pMIGR encoding BCL11B
variants. The transfection procedure was performed using CalPhos
Mammalian Transfection Kit (Clontech Laboratories, CA, USA)
according to the manufacturer’s instructions. The retrovirus-
containing media were collected 48h after transfection and used
immediately or stored at 4uC and used within 7 days. To trans-
duce the target cells, the retroviral supernatants were supplement-
ed with 8 mg/ml Polybrene (Sigma Chemicals, Germany) and
added to exponentially growing Jurkat and huT-78 cells for
8 hours. The procedure was repeated three times. The efficiency
of gene transfer was estimated by FACS detection of EGFP
reporter gene. To ensure high proportion of transduced cells,
EGFP-positive cells were enriched using high-speed cell sorter
FACSAria (BD Biosciences, NJ, USA). Sorted, at least 90%
EGFP-positive cells were used for further experiments.
Apoptosis induction and viability assays
To induce DNA-damage, Jurkat and huT-78 cells transduced
with the empty- and BCL11B-encoding retroviral vectors were
treated with etoposide, camptothecin, actinomycin D or dihy-
droethidium (Sigma, Germany). The influence of histone deace-
tylase inhibition on the viability of mock- and BCL11B-modified
cells was verified using increasing concentrations of trichostatin A,
nicotinamide (Sigma, Germany) or SAHA (Cayman Chemicals,
MI, USA). To investigate the role of histone deacetylases in DNA
damage resistance of BCL11B-overexpressing cells, the treatment
was combined with damage induction using etoposide. Death-
receptor pathway was activated by TRAIL (ProImmune Ltd.,
United Kingdom). Where indicated, incubation with etoposide
was combined with the ABT-737 Bcl-2/BCLxL- inhibitor
treatment (Abbott Laboratories, Il, USA). The long term survival
upon genotoxic stress was initiated by 6 hours pulse treatment
with radiomimetic drugs followed by extensive washing and 14
days cell culture accompanied by cell counting every 48 hours.
Apoptosis was measured by FACS using Annexin V-APC binding
assay (BD Pharmingen, CA, USA). The activation of caspase 3
and 8 was quantified by immunofluorescent detection of the
cleaved variants followed by FACS analysis. In brief, mock- and
BCL11B-transduced Jurkat and huT-78 cells were fixed/permea-
bilized using Cytofix/Cytoperm kit (BD Pharmingen, CA, USA)
and incubated with cleaved caspase 3 (Asp175) or cleaved caspase
8 (Asp391) rabbit monoclonal antibodies and subsequent staining
with the secondary goat anti-rabbit IgG F(ab)
2 fragment stained
with APC (Santa Cruz Biotechnology, CA, USA). Activation of
caspase 9 was assayed by western blot using rabbit polyclonal
antibody recognizing the cleaved/active variant of the protein
(Cell Signaling Technology, MA, USA). The integrity of mito-
chondria was evaluated with the live-mitochondria-specific dye
Mitotracker Deep Red FM (Invitrogen, CA, USA) and subsequent
FACS measurements. Activation of Bak1 pro-apoptotic protein
was tested by immunofluorescence using anti-Bak mouse mono-
clonal antibody (clone TC-100, Calbiochem, Merck Chemicals,
Germany) binding the N-terminal domain exposed upon protein
activation and the secondary goat anti-mouse-APC antibody. The
determination of the DNA damage induced by radiomimetic
drugs was performed by immunofluorescence using AlexaFluor
647-labeled anti-phospho-histone H2A.X antibody (cH2A.X, Cell
Signaling, MA, USA) two hours upon treatment initiation. The
relative signals obtained in mock- and BCL11B-transduced Jurkat
and huT-78 cells were measured by FACS. The progress of
apoptosis was monitored at the same time by Annexin-V binding
assay. To further exclude the secondary, apoptosis related DNA
breaks, the same procedure was repeated in the presence of 20 mM
pan-caspase inhibitor Z-VAD (Sigma, Germany).
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Cell cycle status has been determined by propidium iodide
DNA staining and flow cytometry analyses. Briefly, the cells were
washed and resuspended in propidium iodide staining solution
containing RNase A (Sigma, Germany) and incubated in the
dark for 30 min. Flow cytometric analysis was performed in a
FACScalibur instrument (Becton Dickinson, San Jose, CA, USA).
Cell cycle analysis was performed using ModFit LT (Verity
Software House, Topsham, ME, USA). To determine the rate of
G1 to S transition, cells were blocked in G2/M phase with 0,5 mM
nocodazole and the cell cycle analysis was done at different time-
points. In addition, the G1 to S progression was assessed by pulse
treatment with the nucleotide analogue BrdU. BrdU incorpora-
tion, reflecting the speed of cell cycle progression was determined
with a fluorescently labeled antibody and measured by flow
cytometry (APC BrdU Flow Kit, BD Pharmingen, Franklin Lakes,
NJ, USA).
RNA isolation, microarray analysis and quantitative RT-
PCR
Total RNA was isolated from Jurkat cells transduced with
empty and BCL11B encoding vector with Trizol Reagent
(Invitrogen). Affymetrix array analysis was performed using the
One-Cycle Target Labelling and Control Reagents, which contain
the GeneChip Sample Cleanup Module, and Human Genome
U133 Plus 2.0 DNA arrays (Affymetrix, Santa Clara, CA)
according to the manufacturer’s instructions. The subsequent
scanning was performed with the GeneChip Scanner 3000
(Affymetrix). For quantitative RT-PCR (qRT-PCR), RNA was
reverse transcribed with MultiScribe reverse transcriptase (Applied
Biosysytems) using random hexamers. All primers and probes were
synthesized by TibMolBiol (Berlin, Germany). Quantification of
BCL11B mRNA was performed as described elsewhere [24].
Quantification of genes regulated upon BCL11B overexpression
was performed in Jurkat and huT-78 cell lines. In brief, PCR
amplification was performed in a total volume of 25 ml with 2 mlo f
cDNA, 25 pmol of each primer and SYBRH Green PCR Master
Mix. The list of primer sequences is provided in Supplementary
Materials and Methods S1. A non-specific signaling resulting from
primer-dimer formation was ruled out by analyzing the dissoci-
ation curves and agarose gel electrophoresis.
Analysis of protein levels
Sodium dodecyl sulfate polyacrylamide gel electrophoresis was
performed using standard techniques. Equal protein loads were
confirmed by Ponceau staining and by immunodetection of ß-
actin (Sigma). The Bcl11b protein was detected using antibodies
directed against N-terminal, central or C-terminal epitopes (Bethyl
Laboratories, TX, USA). The proteins corresponding to the
regulated genes confirmed by quantitative RT-PCR were detected
with the following antibodies: cleaved Caspase 9 rabbit polyclonal
antibody, p57 rabbit polyclonal antibody, p27 rabbit polyclonal
antibody, p18 mouse monoclonal antibody, Skp2 rabbit polyclonal
antibody, Rb antibody kit, Myc- N rabbit polyclonal antibody
(Cell Signaling Technology, MA, USA) and p130 (RBL2) rabbit
polyclonal antibody (Santa Cruz Biotechnology, CA, USA).
Proteins were visualized by chemiluminescence using rabbit- or
mouse-specific Western-SuperStar
TM Immunodetection system
(Applied Biosystems, Life Technologies, CA, USA).
The intracellular staining of Myc-N was performed in fixed and
permeabilized cells (Cytofix/Cytoperm, BD Pharmingen, Franklin
Lakes, NJ, USA) with N-Myc specific rabbit primary antibody and
subsequent immunodetection using goat anti-rabbit APC-labeled
antibody (Santa Cruz Biotechnology, CA, USA).
Sub-cellular localization of full-length BCL11B and
BCL11B-derived deletion mutants
The wild-type BCL11B coding sequence or alternatively the
truncated variants of the gene were cloned in-frame into pEGFP-
C1 plasmid vector (Clontech Laboratories, CA, USA) downstream
of the enhanced green fluorescent protein (EGFP). The plasmid
vectors were transfected into Jurkat cells using the Nucleofector
device (Lonza, Switzerland). After 12–24 hours incubation, cells
were fixed and the EGFP expression and localization was
determined by fluorescence microscopy.
Supporting Information
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0012532.s001 (0.03 MB
DOC)
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